Exact Mass: 548.2383
Exact Mass Matches: 548.2383
Found 500 metabolites which its exact mass value is equals to given mass value 548.2383
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Bruceantin
Bruceantin is a triterpenoid. Bruceantin is a natural product found in Brucea javanica and Brucea antidysenterica with data available. Bruceantin is a triterpene quassinoid antineoplastic antibiotic isolated from the plant Brucea antidysenterica. Bruceantin inhibits the peptidyl transferase elongation reaction, resulting in decreased protein and DNA synthesis. Bruceantin also has antiamoebic and antimalarial activity. (NCI04) C274 - Antineoplastic Agent > C1931 - Antineoplastic Plant Product > C1974 - Quassinoid Agent C784 - Protein Synthesis Inhibitor C1907 - Drug, Natural Product Bruceantin (NSC165563) can be extracted from B. javanica and has inhibitory effects on B16 melanoma, colon cancer 38, L1210 and leukemia P388. Bruceantin (NSC165563) can be extracted from B. javanica and has inhibitory effects on B16 melanoma, colon cancer 38, L1210 and leukemia P388.
PA(2:0/PGE2)
PA(2:0/PGE2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/PGE2), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Prostaglandin E2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(PGE2/2:0)
PA(PGE2/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGE2/2:0), in particular, consists of one chain of one Prostaglandin E2 at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(2:0/PGD2)
PA(2:0/PGD2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/PGD2), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Prostaglandin D2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(PGD2/2:0)
PA(PGD2/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGD2/2:0), in particular, consists of one chain of one Prostaglandin D2 at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(2:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))
PA(2:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Lipoxin A4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/2:0)
PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/2:0), in particular, consists of one chain of one Lipoxin A4 at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
3,7-Dihydroxy-4,5-dimethoxy-8-prenylflavan 7-O-beta-D-glucopyranoside
[3R-(3alpha,4beta,5alpha,5aalpha,6alpha,9beta,9aalpha,10R*)]-5a-[(Acetyloxy)methyl]octahydro-2,2,9-trimethyl-2H-3,9a-methano-1-benzoxepin-4,5,6,9,10-pentol 5,10-diacetate 6-benzoate
6R,7E,9R-megastigma-4,7-dien-3-one 9,13-di-O-beta-D-glucopyranoside
4,8-dihydroxy-3-methoxy-11-oxo-1,6-dipentyl-11H-dibenzo[b,e][1,4]dioxepine-7-carboxylic acid benzyl ester
1alpha,2alpha,6beta-Triacetoxy-9alpha-benzoyloxy-8alpha,15-dihydroxydihydro-beta-agarofuran
(Ra)-3-phenylacrylic acid 7-hydroxy-2,3,10,11,12-pentamethoxy-6,7-dimethyl-5,6,7,8-tetrahydrodibenzo[a,c]cycloocten-1-yl ester|neglschisandrin C
(1alpha,11beta)-23-ethoxy-1,2,21,23-tetrahydro-1,11-dihydroxy-21-oxoobacunone|23-ethoxy-21,23-dihydro-21-oxoclausenarin
1S,4S,5S,6R,7R,8R,9S,10S-9-benzoyloxy-1,6,15-triacetoxy-4,8-dihydroxy-dihydro-beta-agarofuran
6,9-dihydroxymegastigmasta-5,7-dien-3-one 9-O-beta-D-gentiobioside
1S,4S,5S,6R,7R,8R,9S,10S-9-benzoyloxy-6,8,15-triacetoxy-1,4-dihydroxy-dihydro-beta-agarofuran
bistratamide I
A homodetic cyclic peptide that consists of L-valine and L-threonine as the amino acid residues. It is isolated from Lissoclinum bistratum and exhibits antitumour activity against the human colon tumour cell line.
(1R*,2R*,3R*,5Z,7S*,8(17)E,9S*,10S*,11R*,12S*,14S*)-2,3,9,14-tetraacetoxy-11,12-epoxybriara-5,8(17)-dien-18-one|excavatolide S
(1R*)-1-(furan-3-yl)-2-[(6aR,7R,8S,9R,10aS)-9-(beta-D-ribo-hexopyranosyl-3-uloseoxy)-3,5,6,6a,7,8,9,10-octahydro-7,8-dimethyl-3-oxonaphtho[1,8a-c]furan-7-yl]ethyl acetate|15,16-epoxy-12alpha-O-acetylcleroda-3,13(16),14-triene-18,19-olide-7alpha-O-beta-D-ribohexo-3-ulopyranoside|splendidin C
Ala Ser Trp Trp
Ala Trp Ser Trp
Ala Trp Trp Ser
Cys Asp Arg Arg
Cys Ile Gln Trp
Cys Ile Trp Gln
Cys Leu Gln Trp
Cys Leu Trp Gln
Cys Gln Ile Trp
Cys Gln Leu Trp
Cys Gln Trp Ile
Cys Gln Trp Leu
Cys Arg Asp Arg
Cys Arg Arg Asp
Cys Trp Ile Gln
Cys Trp Leu Gln
Cys Trp Gln Ile
Cys Trp Gln Leu
Asp Cys Arg Arg
Asp Met Gln Arg
Asp Met Arg Gln
Asp Gln Met Arg
Asp Gln Arg Met
Asp Gln Thr Trp
Asp Gln Trp Thr
Asp Arg Cys Arg
Asp Arg Met Gln
Asp Arg Gln Met
Asp Arg Arg Cys
Asp Thr Gln Trp
Asp Thr Trp Gln
Asp Trp Gln Thr
Asp Trp Thr Gln
Glu His Thr Tyr
Glu His Tyr Thr
Glu Met Asn Arg
Glu Met Arg Asn
Glu Asn Met Arg
Glu Asn Arg Met
Glu Asn Thr Trp
Glu Asn Trp Thr
Glu Gln Ser Trp
Glu Gln Trp Ser
Glu Arg Met Asn
Glu Arg Asn Met
Glu Ser Gln Trp
Glu Ser Trp Gln
Glu Thr His Tyr
Glu Thr Asn Trp
Glu Thr Trp Asn
Glu Thr Tyr His
Glu Trp Asn Thr
Glu Trp Gln Ser
Glu Trp Ser Gln
Glu Trp Thr Asn
Glu Tyr His Thr
Glu Tyr Thr His
Phe Gly Tyr Tyr
Phe Tyr Gly Tyr
Phe Tyr Tyr Gly
Gly Phe Tyr Tyr
Gly Met Arg Trp
Gly Met Trp Arg
Gly Arg Met Trp
Gly Arg Trp Met
Gly Thr Trp Trp
Gly Trp Met Arg
Gly Trp Arg Met
Gly Trp Thr Trp
Gly Trp Trp Thr
Gly Tyr Phe Tyr
Gly Tyr Tyr Phe
His Glu Thr Tyr
His Glu Tyr Thr
His His Gln Gln
His Met Val Tyr
His Met Tyr Val
His Gln His Gln
His Gln Gln His
His Thr Glu Tyr
His Thr Tyr Glu
His Val Met Tyr
His Val Tyr Met
His Tyr Glu Thr
His Tyr Met Val
His Tyr Thr Glu
His Tyr Val Met
Ile Cys Gln Trp
Ile Cys Trp Gln
Ile Gln Cys Trp
Ile Gln Trp Cys
Ile Trp Cys Gln
Ile Trp Gln Cys
Leu Cys Gln Trp
Leu Cys Trp Gln
Leu Gln Cys Trp
Leu Gln Trp Cys
Leu Trp Cys Gln
Leu Trp Gln Cys
Met Asp Gln Arg
Met Asp Arg Gln
Met Glu Asn Arg
Met Glu Arg Asn
Met Gly Arg Trp
Met Gly Trp Arg
Met His Val Tyr
Met His Tyr Val
Met Asn Glu Arg
Met Asn Arg Glu
Met Asn Val Trp
Met Asn Trp Val
Met Gln Asp Arg
Met Gln Arg Asp
Met Arg Asp Gln
Met Arg Glu Asn
Met Arg Gly Trp
Met Arg Asn Glu
Met Arg Gln Asp
Met Arg Trp Gly
Met Val His Tyr
Met Val Asn Trp
Met Val Trp Asn
Met Val Tyr His
Met Trp Gly Arg
Met Trp Asn Val
Met Trp Arg Gly
Met Trp Val Asn
Met Tyr His Val
Met Tyr Val His
Asn Glu Met Arg
Asn Glu Arg Met
Asn Glu Thr Trp
Asn Glu Trp Thr
Asn Met Glu Arg
Asn Met Arg Glu
Asn Met Val Trp
Asn Met Trp Val
Asn Arg Glu Met
Asn Arg Met Glu
Asn Thr Glu Trp
Asn Thr Trp Glu
Asn Val Met Trp
Asn Val Trp Met
Asn Trp Glu Thr
Asn Trp Met Val
Asn Trp Thr Glu
Asn Trp Val Met
Gln Cys Ile Trp
Gln Cys Leu Trp
Gln Cys Trp Ile
Gln Cys Trp Leu
Gln Asp Met Arg
Gln Asp Arg Met
Gln Asp Thr Trp
Gln Asp Trp Thr
Gln Glu Ser Trp
Gln Glu Trp Ser
Gln His His Gln
Gln His Gln His
Gln Ile Cys Trp
Gln Ile Trp Cys
Gln Leu Cys Trp
Gln Leu Trp Cys
Gln Met Asp Arg
Gln Met Arg Asp
Gln Gln His His
Gln Arg Asp Met
Gln Arg Met Asp
Gln Ser Glu Trp
Gln Ser Trp Glu
Gln Thr Asp Trp
Gln Thr Trp Asp
Gln Trp Cys Ile
Gln Trp Cys Leu
Gln Trp Asp Thr
Gln Trp Glu Ser
Gln Trp Ile Cys
Gln Trp Leu Cys
Gln Trp Ser Glu
Gln Trp Thr Asp
Arg Cys Asp Arg
Arg Cys Arg Asp
Arg Asp Cys Arg
Arg Asp Met Gln
Arg Asp Gln Met
Arg Asp Arg Cys
Arg Glu Met Asn
Arg Glu Asn Met
Arg Gly Met Trp
Arg Gly Trp Met
Arg Met Asp Gln
Arg Met Glu Asn
Arg Met Gly Trp
Arg Met Asn Glu
Arg Met Gln Asp
Arg Met Trp Gly
Arg Asn Glu Met
Arg Asn Met Glu
Arg Gln Asp Met
Arg Gln Met Asp
Arg Arg Cys Asp
Arg Arg Asp Cys
Arg Trp Gly Met
Arg Trp Met Gly
Ser Ala Trp Trp
Ser Glu Gln Trp
Ser Glu Trp Gln
Ser Gln Glu Trp
Ser Gln Trp Glu
Ser Trp Ala Trp
Ser Trp Glu Gln
Ser Trp Gln Glu
Ser Trp Trp Ala
Thr Asp Gln Trp
Thr Asp Trp Gln
Thr Glu His Tyr
Thr Glu Asn Trp
Thr Glu Trp Asn
Thr Glu Tyr His
Thr Gly Trp Trp
Thr His Glu Tyr
Thr His Tyr Glu
Thr Asn Glu Trp
Thr Asn Trp Glu
Thr Gln Asp Trp
Thr Gln Trp Asp
Thr Trp Asp Gln
Thr Trp Glu Asn
Thr Trp Gly Trp
Thr Trp Asn Glu
Thr Trp Gln Asp
Thr Trp Trp Gly
Thr Tyr Glu His
Thr Tyr His Glu
Val His Met Tyr
Val His Tyr Met
Val Met His Tyr
Val Met Asn Trp
Val Met Trp Asn
Val Met Tyr His
Val Asn Met Trp
Val Asn Trp Met
Val Trp Met Asn
Val Trp Asn Met
Val Tyr His Met
Val Tyr Met His
Trp Ala Ser Trp
Trp Ala Trp Ser
Trp Cys Ile Gln
Trp Cys Leu Gln
Trp Cys Gln Ile
Trp Cys Gln Leu
Trp Asp Gln Thr
Trp Asp Thr Gln
Trp Glu Asn Thr
Trp Glu Gln Ser
Trp Glu Ser Gln
Trp Gly Met Arg
Trp Gly Arg Met
Trp Gly Thr Trp
Trp Gly Trp Thr
Trp Ile Cys Gln
Trp Ile Gln Cys
Trp Leu Cys Gln
Trp Leu Gln Cys
Trp Met Gly Arg
Trp Met Asn Val
Trp Met Arg Gly
Trp Met Val Asn
Trp Asn Met Val
Trp Asn Val Met
Trp Gln Cys Ile
Trp Gln Cys Leu
Trp Gln Glu Ser
Trp Gln Ile Cys
Trp Gln Leu Cys
Trp Gln Ser Glu
Trp Gln Thr Asp
Trp Arg Gly Met
Trp Arg Met Gly
Trp Ser Ala Trp
Trp Ser Glu Gln
Trp Ser Gln Glu
Trp Ser Trp Ala
Trp Thr Asp Gln
Trp Thr Glu Asn
Trp Thr Gly Trp
Trp Thr Asn Glu
Trp Thr Gln Asp
Trp Thr Trp Gly
Trp Val Met Asn
Trp Val Asn Met
Trp Trp Ala Ser
Trp Trp Gly Thr
Trp Trp Ser Ala
Trp Trp Thr Gly
Tyr Glu His Thr
Tyr Glu Thr His
Tyr Phe Gly Tyr
Tyr Phe Tyr Gly
Tyr Gly Phe Tyr
Tyr Gly Tyr Phe
Tyr His Glu Thr
Tyr His Met Val
Tyr His Thr Glu
Tyr His Val Met
Tyr Met His Val
Tyr Met Val His
Tyr Thr Glu His
Tyr Thr His Glu
Tyr Val His Met
Tyr Val Met His
Tyr Tyr Phe Gly
Tyr Tyr Gly Phe
ICG-001
butane-1,4-diol,ethane-1,2-diol,hexanedioic acid,1-isocyanato-4-[(4-isocyanatophenyl)methyl]benzene
Bruceanol F
A quassinoid isolated from Brucea antidysenterica and has been shown to exhibit in vitro cytotoxicity towards several human tumour cell lines.
(6R,9aR)-6-[(4-hydroxyphenyl)methyl]-8-(1-naphthalenylmethyl)-4,7-dioxo-N-(phenylmethyl)-3,6,9,9a-tetrahydro-2H-pyrazino[1,2-a]pyrimidine-1-carboxamide
Terbutaline sulfate
D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013566 - Sympathomimetics C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D012102 - Reproductive Control Agents > D015149 - Tocolytic Agents
(2S,3S,4S,5R)-6-[(3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-[(2R)-4-[(1R)-2,6,6-trimethyl-4-oxocyclohex-2-en-1-yl]butan-2-yl]oxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
Picras-3-en-21-oic acid, 15-((3,4-dimethyl-1-oxo-2-pentenyl)oxy)-13,20-epoxy-1,11,12-trihydroxy-2,16-dioxo-,methyl ester, (1beta,11beta,12alpha,15beta(E))-
1-[[(2R,3R)-8-[(3S)-3-hydroxybut-1-ynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea
1-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-[4-(trifluoromethyl)phenyl]urea
1-[[(2R,3R)-8-[(3R)-3-hydroxybut-1-ynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea
1-[[(2S,3R)-8-[(3S)-3-hydroxybut-1-ynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea
1-[[(2S,3S)-8-[(3S)-3-hydroxybut-1-ynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea
1-[[(2R,3S)-8-[(3R)-3-hydroxybut-1-ynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea
1-[[(2S,3R)-8-[(3S)-3-hydroxybut-1-ynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea
1-[[(2R,3S)-8-[(3R)-3-hydroxybut-1-ynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea
1-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-[4-(trifluoromethyl)phenyl]urea
1-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-[4-(trifluoromethyl)phenyl]urea
1-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-[4-(trifluoromethyl)phenyl]urea
N-[(2R,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-(2-thiazolyl)benzamide
1-[[(2S,3S)-8-[(3R)-3-hydroxybut-1-ynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea
1-[[(2R,3S)-8-[(3S)-3-hydroxybut-1-ynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea
1-[[(2R,3R)-8-[(3S)-3-hydroxybut-1-ynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea
1-[[(2R,3S)-8-[(3S)-3-hydroxybut-1-ynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea
1-[[(2S,3S)-8-[(3R)-3-hydroxybut-1-ynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea
1-[[(2S,3R)-8-[(3R)-3-hydroxybut-1-ynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea
1-[[(2S,3R)-8-[(3R)-3-hydroxybut-1-ynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea
1-[[(2S,3S)-8-[(3S)-3-hydroxybut-1-ynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea
1-[[(2R,3R)-8-[(3R)-3-hydroxybut-1-ynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea
(2R)-2-[(4S,5R)-8-[2-(2-methoxyphenyl)ethynyl]-4-methyl-5-[[methyl-(phenylmethyl)amino]methyl]-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
(2S)-2-[(4S,5R)-8-[2-(2-methoxyphenyl)ethynyl]-4-methyl-5-[[methyl-(phenylmethyl)amino]methyl]-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
1-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-[4-(trifluoromethyl)phenyl]urea
1-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-[4-(trifluoromethyl)phenyl]urea
1-[(1R,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-[4-(trifluoromethyl)phenyl]urea
1-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-[4-(trifluoromethyl)phenyl]urea
bruceanol D
A quassinoid natural product found in Brucea antidysenterica consisting of a heteropentacyclic skeleton containing a delta-lactone moiety which is substituted at the alpha-carbon by a (2E)-3,4-dimethylpent-2-enoyloxy group. It shows significant in vitro cytotoxicity towards several human tumour cell lines.
[2,12,14-tris(acetyloxy)-3-hydroxy-4,13-dimethyl-17-methylidene-5-oxo-6-oxatricyclo[11.4.0.0³,⁷]heptadeca-8,10-dien-9-yl]methyl acetate
7-ethenyl-12-ethyl-21-hydroxy-6,11,27,28-tetramethyl-20-oxa-2,16,29,30-tetraazaheptacyclo[15.8.1.1³,²⁵.1⁵,⁸.1¹⁰,¹³.1¹⁵,¹⁸.0²¹,²⁶]triaconta-1,3,5,7,9,11,13(29),14,17(26),18(28)-decaene-19,22-dione
(8r,21s)-27-methoxy-22-methyl-15,29,31-trioxa-7,22-diazaoctacyclo[19.9.3.2¹⁶,¹⁹.1⁴,³⁰.1¹⁰,¹⁴.0³,⁸.0²⁵,³³.0²⁸,³²]heptatriaconta-1,3,10,12,14(37),16,18,25(33),26,28(32),30(34),35-dodecaen-13-ol
4-hydroxy-2,5-bis[1-(2-methylbut-3-en-2-yl)indol-3-yl]-3,6-dioxocyclohexa-1,4-dien-1-yl acetate
(1r,2r,4s,6r,7s,9s,10s,11s,13r)-2,6,7-tris(acetyloxy)-13-hydroxy-5,5,9-trimethyl-14-methylidene-3,15-dioxotetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-11-yl acetate
7,12-bis(acetyloxy)-6-[(acetyloxy)methyl]-2,8-dihydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-5-yl benzoate
artanomaloide
{"Ingredient_id": "HBIN016925","Ingredient_name": "artanomaloide","Alias": "NA","Ingredient_formula": "C32H36O8","Ingredient_Smile": "CC1=C2C(C3C(C(C1)OC(=O)C)C4(CC56C=CC4(C5C7C(CCC6(C)O)C(=C)C(=O)O7)C)C(=O)O3)C(=CC2=O)C","Ingredient_weight": "548.62","OB_score": "NA","CAS_id": "112823-41-3","SymMap_id": "NA","TCMID_id": "1781","TCMSP_id": "NA","TCM_ID_id": "6624","PubChem_id": "102005656","DrugBank_id": "NA"}